从目前的抗VEGF疗法转换为法里西马布:基于证据的专家建议
David T Wong1, Shaheer Aboobaker2, David Maberley3
1Ophthalmology & Vision Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada david.wong@unityhealth.to.
BMJ open ophthalmology
|January 17, 2025
概括
针对血管内皮素 (Ang) 和血管内皮生长因子 (VEGF) 途径的双重抑制与法里西马布为视网膜疾病提供了改善的血管稳定性. 这种方法提高了治疗效率和耐久性,而不是仅使用VEGF的疗法.
科学领域:
- 眼科医生 眼科 眼科
- 血管生物学 血管生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 神经血管与年龄相关的黄斑变性 (nAMD) 和糖尿病黄斑 (DME) 是导致视力丧失的主要原因.
- 目前的治疗主要针对血管内皮生长因子 (VEGF) 途径.
- 抗血管素 (Ang) /Tie和VEGF通路的双重抑制可能提供优越的血管稳定性和治疗结果.
研究的目的:
- 为在患有nAMD或DME的患者中最佳使用法里西马布提供专家建议.
- 巩固目前关于法里西马布治疗的证据和临床经验.
- 专注于从抗VEGF单一疗法过渡到法里西马布.
主要方法:
- 对法里西马布的临床试验数据和现实世界的证据的审查.
- 专家小组就治疗策略达成共识.
- 分析法里西马布在抑制Ang-2和VEGF通路中的有效性.
主要成果:
- 费里西马布是第一种可注射的眼科药物,可在nAMD和DME治疗中使用长达16周的治疗间隔.
- 第三阶段研究表明,视觉敏度和视网膜厚度有所改善.
- 现实数据证实了法里西马布的安全性,疗效和耐久性,包括以前用其他药物治疗的患者.
结论:
- 与法里西马布的双抑制提供了显著的血管稳定性,改善了nAMD和DME的疗效和耐久性.
- 法里西马布可提供延长治疗间隔和持续的视觉和解剖效益.
- 专家建议支持法里西马布作为一个有价值的选择,特别是在从抗VEGF单疗转换时.
更多相关视频
09:24Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells
Published on: September 18, 2019
9.8K
05:14Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
Published on: August 11, 2023
1.0K
相关概念视频
01:27Tumor Immunotherapy
468
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
468
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K